Previous 10 | Next 10 |
NEW YORK and LONDON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, toda...
Akari Therapeutics (NASDAQ: AKTX ): Q2 GAAP EPS of $0.00 beats by $0.27 . More news on: Akari Therapeutics, Plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
- Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April 2019 Phase I/II clinical study in patients with moderate-to-severe atopic keraconjunctivitis (AKC) announced June 2019 ...
Briggs & Stratton (NYSE: BGG ) -47% . on Q4 earnings & dividend cut. More news on: Briggs & Stratton Corporation, Just Energy Group Inc., Akari Therapeutics, Plc, Stocks on the move, Read more ...
It’s not easy to get approval from the FDA. There are steps to follow, standards to meet. Sometimes, companies fail. But Akari Therapeutics (NASDAQ:AKTX) is not one of them, receiving Fast Track approval from the federal agency this week. On the news, AKTX stock jumped, currently u...
Gainers: Infrastructure and Energy Alternatives (NASDAQ: IEA ) +61% . Novavax (NASDAQ: NVAX ) +40% . Akari Therapeutics (NASDAQ: AKTX ) +31% . Xunlei Limited (NASDAQ: XNET ) +30% . Presidio (NASDAQ: PSDO ) +21% . Purple Innovation (NASDAQ: PRPL ) +22% . InMode (NASDAQ: INMD ) ...
Akari Therapeutics (NASDAQ: AKTX ) +57% as nomacopan Fast Track'd for HSCT-TMA. More news on: Akari Therapeutics, Plc, InMode Ltd., Presidio, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 62% premarket on robust volume in reaction to the FDA's granting of Fast Track status for Coversin (nomacopan) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA...
Fast Track designation by the U.S. Food and Drug Administration (FDA) facilitates the development and expedites the review of new medicines like nomacopan that treat serious unmet medical needs and in Akari’s case, pediatric patients with HSCT-TMA. The Fast Track designat...
New data from bullous pemphigoid (BP) patients and pemphigoid disease (PD) models generated by Dr. Christian Sadik’s group at University of Lubeck, Germany published in the August 2019 edition of JCI Insight (see link to article HERE ) Preclinical PD model shows maxima...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...